Previous 10 | Next 10 |
RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult and pediatric) RMAT designation enables increased dialogue with the FDA to support t...
2024-04-12 11:34:12 ET More on S&P 500 Index: Sticking With The More Optimistic View Where We Stand Sorry Campers, The Fed Is Not Riding To The Rescue Nasdaq, S&P, Dow slip as major banks kick off earnings season Nasdaq, S&P climb, Dow end...
2024-04-09 15:16:37 ET More on Taysha Gene Therapies Taysha: Initial Rett Syndrome Data Leads To Other 2024 Catalysts Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript Taysha Gene Therapies, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
2024-04-09 10:00:07 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Well...
2024-04-09 05:00:04 ET Christopher Raymond from Raymond James issued a price target of $9.00 for TSHA on 2024-04-09 03:56:00. The adjusted price target was set to $9.00. At the time of the announcement, TSHA was trading at $2.68. The overall price target consensus is at ...
2024-03-20 12:38:33 ET There was some pretty substantial news coming out of Dallas, TX this morning after a %Biotech company shared initial clinical data from the first pediatric patient from the REVEAL Phase ½ adolescent and adult trial of TSHA-102, an investigational gene therapy...
2024-03-20 12:30:27 ET Summary Taysha Gene Therapies, Inc. cohort 2 higher dosing TSHA-102 data from adolescent and adult phase 1/2 REVEAL study treating patients with Rett Syndrome is expected in 2nd half of 2024. Cohort 1 data of TSHA-102 treating pediatric patients with Rett Sy...
2024-03-20 12:25:51 ET More on Mid-day movers & stocks. Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript Personalis Q4 2023 Earnings Preview XTI Aircraft that will merge with Inpixon gets Chinese patent for an aircraft Seeking Alpha’s Quant...
2024-03-20 10:13:02 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&...
2024-03-20 08:15:10 ET More on Taysha Gene Therapies Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript Taysha Gene Therapies, Inc. 2023 Q4 - Results - Earnings Call Presentation Taysha: Produces Solid Data But Has Abandoned Programs Taysha t...
News, Short Squeeze, Breakout and More Instantly...
Taysha Gene Therapies Inc. Company Name:
TSHA Stock Symbol:
NASDAQ Market:
2024-05-28 13:15:05 ET Piper Sandler analyst issues MARKET OUTPERFORM recommendation for TSHA on May 28, 2024 11:00AM ET. The previous analyst recommendation was Market Outperform. TSHA was trading at $3.145 at issue of the analyst recommendation. The overall analyst con...
2024-05-28 13:15:05 ET Needham analyst issues UNDERPERFORM recommendation for TSHA on May 28, 2024 11:00AM ET. The previous analyst recommendation was Underperform. TSHA was trading at $3.145 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Completed dosing in cohort one (low dose, 5.7x10 14 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102; enrolled first patient in cohort two (high dose, 1x10 15 total vg) with dosing...